bace1-in-2

BACE1-IN-2 is a BACE1 inhibitor (IC50: 22 nM).

BACE1/2-IN-1 (compound 34) is an effective BACE1 and BACE2 inhibitor with IC50 values of 0.01 and 0.0053 μM, respectively. It exhibits a lower Pgp efflux ratio, improved passive permeability, and decreased metabolic stability in liver microsomes.

Auraptene is a coumarin derived from citrus plants that bears a geranyloxyl moiety at its C-7. It has anti-inflammatory, anti-carcinogenic, anti-bacterial, neuroprotective, and hepatoprotective activities. It inhibits leukocyte activation and induces phas

BACE1-IN-15 (Compound 72) is a selective β-secretase 1 (BACE-1) inhibitor with oral bioavailability and blood-brain barrier permeability, exhibiting an IC50 value of 121.65 nM, and an IC50 of 480.92 nM for BACE-2. BACE1-IN-15 is applicable for research in the field of Alzheimer's disease.

Timosaponin BII (Prototimosaponin A III) exhibits anti-dementia and antioxidant activities, with potential applications in treating type 2 diabetes. It can inhibit the up-regulation of BACE1 and reduce the over-production of β-CTF and Aβ in rat retina induced by FeCl.

6,9-Dichloro-1,2,3,4-tetrahydroacridine is a synthetic intermediate in the synthesis of tacrine-based acetylcholinesterase (AChE) inhibitors.1It is also an intermediate in the synthesis of multifunctional tacrine hybrids that possess radical scavenging, amyloid-β aggregation inhibitory, and/or β-secretase 1 (BACE1) inhibitory activities in addition to their activity as AChE inhibitors.2,3 1.Recanatini, M., Cavalli, A., Belluti, F., et al.SAR of 9-amino-1,2,3,4-tetrahydroacridine-based acetylcholinesterase inhibitors: Synthesis, enzyme inhibitory activity, QSAR, and structure-based CoMFA of tacrine analoguesJ. Med. Chem.43(10)2007-2018(2000) 2.Digiacomo, M., Chen, Z., Wang, S., et al.Synthesis and pharmacological evaluation of multifunctional tacrine derivatives against several disease pathways of ADBioorg. Med. Chem. Lett.25(4)807-810(2015) 3.Li, S.Y., Jiang, N., Xie, S.S., et al.Design, synthesis and evaluation of novel tacrine-rhein hybrids as multifunctional agents for the treatment of Alzheimer's diseaseOrg. Biomol. Chem.12(5)801-814(2014)

OM99-2 TFA is an eight-residue peptidomimetic compound, functioning as a tight-binding inhibitor of human brain memapsin 2. It exhibits a high affinity for the target with a Ki value of 9.58 nM, making it a promising candidate in the development of BACE1 inhibitors. Due to its potential, OM99-2 presents opportunities for further research in the field of Alzheimer's disease.

OM99-2 is an eight-residue peptidomimetic with a high affinity for human brain memapsin 2, exhibiting a Ki value of 9.58 nM. This compound represents a significant advancement in the development of BACE1 inhibitors and holds potential for the study of Alzheimer's disease.

Auraptene (Standard) is a reference standard for research and analysis in studies involving Auraptene. Auraptene is a coumarin derived from citrus plants that bears a geranyloxyl moiety at its C-7. It has anti-inflammatory, anti-carcinogenic, anti-bacterial, neuroprotective, and hepatoprotective activities. It inhibits leukocyte activation and induces phase II enzymes during the initiation phase of carcinogenesis.1 When examined for its potential use in Alzheimer's disease treatment, auraptene was shown to inhibit β-secretase (BACE1) activity with an IC50 value of 345.1 μM.

Timosaponin BII (Standard) is a reference standard for research and analysis in studies involving Timosaponin BII. Timosaponin BII (Prototimosaponin A III) has anti-dementia activity and may be useful for the treatment of type 2 diabetes. Timosaponin BII has antioxidant activity, can inhibit the up-regulation of BACE1 and reduced the over-production of β-CTF and Aβ in rat retina, which was induced by FeCl .